NASDAQ · ROIV
Healthcare · Biotechnology
$35.78
Up+$0.06 (+0.17%)
Updated Oct 6, 2026, 3:39 AM
SID Score
6.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance · ROIV
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 5, 2026
ROIV closed at $35.78 after 20 trading sessions, down 13.74% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 5, 2026 | $35.98 | $36.325 | $35.245 | $35.78 | 6.2M |
| Oct 2, 2026 | $35.61 | $36.00 | $35.19 | $35.72 | 4.37M |
| Oct 1, 2026 | $36.35 | $36.79 | $35.435 | $35.50 | 3.27M |
| Sep 30, 2026 | $36.77 | $36.955 | $36.23 | $36.57 | 5.28M |
| Sep 29, 2026 | $37.03 | $37.345 | $35.75 | $36.50 | 6.59M |
| Sep 28, 2026 | $35.65 | $37.245 | $35.28 | $36.98 | 6.97M |
| Sep 25, 2026 | $35.98 | $36.19 | $35.515 | $35.80 | 6.76M |
| Sep 24, 2026 | $36.64 | $36.75 | $35.905 | $36.13 | 5.66M |
| Sep 23, 2026 | $38.00 | $38.47 | $36.78 | $36.82 | 9.27M |
| Sep 22, 2026 | $38.73 | $39.17 | $38.11 | $38.22 | 6.75M |
| Sep 21, 2026 | $39.02 | $39.90 | $38.72 | $38.99 | 5.62M |
| Sep 18, 2026 | $40.11 | $40.71 | $39.715 | $39.77 | 32.2M |
| Sep 17, 2026 | $40.445 | $40.97 | $39.50 | $39.98 | 7.6M |
| Sep 16, 2026 | $39.77 | $40.445 | $39.165 | $39.57 | 6.18M |
| Sep 15, 2026 | $41.14 | $41.14 | $39.215 | $39.50 | 8.1M |
| Sep 14, 2026 | $40.64 | $41.60 | $40.44 | $41.02 | 7.59M |
| Sep 11, 2026 | $41.22 | $41.83 | $40.51 | $40.82 | 5.96M |
| Sep 10, 2026 | $41.265 | $41.405 | $40.215 | $40.94 | 6.54M |
| Sep 9, 2026 | $41.39 | $42.275 | $41.0808 | $41.81 | 11.15M |
| Sep 8, 2026 | $39.98 | $42.50 | $38.41 | $41.48 | 24.67M |
The latest Smart Investors Daily articles mentioning ROIV.
Company
Market Activity
Research & News
ROIV research
Company profile and research snapshot.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 17, 2026 | Stifel | Buy | — |
| Sep 9, 2026 | TD Cowen | Buy | — |
| Sep 9, 2026 | Guggenheim | Buy | — |
| Sep 8, 2026 | Jefferies | Buy | — |
| Sep 8, 2026 | HC Wainwright & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Oct 1, 2026
Roivant Sciences (NASDAQ:ROIV) has outperformed the market over the past 5 years by 27.07% on an annualized basis producing an average annual return of 39.09%. Currently, Roivant Sciences has a market capitalization of
Yahoo · Sep 24, 2026
Roivant Sciences Ltd. (NASDAQ:ROIV) shares jumped about 17% after the company reported positive mid-stage results for mosliciguat, its experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). The readout gives Roivant (NASDAQ:ROIV) another late-stage pipeline opportunity shortly after the company won U.S. approval for Lisraya, its treatment for adults with dermatomyositis. READ ALSO: […]
SeekingAlpha · Sep 22, 2026
Roivant Sciences Ltd. (ROIV) Bank of America Global Healthcare Conference 2026 September 22, 2026 8:20 AM EDTCompany ParticipantsMatthew Gline - CEO &...
Yahoo · Sep 22, 2026
Roivant Sciences Ltd. (NASDAQ:ROIV) may be entering the most important phase of its business, as its pipeline begins to move from clinical development to commercialization. Stifel initiated coverage of Roivant with a Buy rating and a $51 price target on September 16. The target implied a roughly 29% upside from the stock price at that […]
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ROIV.
